Bio Pharma Dive
FEBRUARY 1, 2022
The collaboration with GenEdit, a South San Francisco startup developing new ways of delivering gene editing tools into the body, dates back to December 2020, but has recently begun to advance.
World of DTC Marketing
FEBRUARY 3, 2022
The way people make treatment decisions is changing because of COVID. Agencies are responsible for working with clients to implement changes that support brand objectives. It won’t be easy and means changing the mindset from a vendor to a strategic partner. If you work in an agency, your job is not to develop a website or TV spot. You need to work with pharma clients to educate them on the complicated path from awareness to requesting an Rx.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 1, 2022
A study has shown that a ‘smart’ stethoscope developed by US digital health company Eko can be used to screen people for heart failure in a few second during a standard physical examination. The device tested in the independent study combines a stethoscope used to listen to heart sounds with a single-lead electrocardiogram (ECG). It uses an algorithm to detects low left ventricular ejection fraction (LVEF) – reduced outflow of blood from the heart to the aorta – which is a common cha
Pharma Times
FEBRUARY 3, 2022
Significant landmark as NICE recommends AstraZeneca's chronic kidney disease treatment Forxiga
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
FEBRUARY 1, 2022
William Pao led discovery and early development at the Swiss drugmaker, and will now head Pfizer's global efforts to launch new products.
World of DTC Marketing
FEBRUARY 2, 2022
Biogen will partner with Roche on the development, and potential sale of a promising cancer drug the Swiss pharma is advancing for several types of lymphoma, announcing Tuesday it’s exercised an option to share rights to the treatment. But is it too late for Biogen to stage a comeback with their reputation damaged? Biogen executives vowed to fight hard to reverse Medicare’s preliminary decision to sharply limit coverage of the company’s Alzheimer’s drug while saying more
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
FEBRUARY 4, 2022
Pharma giant Sanofi continues to modernise with branding which reflects its commitment to social responsibility and sustainability
Bio Pharma Dive
FEBRUARY 4, 2022
Gene therapy developers have struggled to secure reimbursement in Europe, making Orchard's deal with the National Health Service in England and Wales a notable accomplishment.
World of DTC Marketing
FEBRUARY 1, 2022
According to STAT News “after a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. Can small biotech companies survive? Many large pharmaceutical companies reported record performances in 2021, whether that’s a decade-high stock price or shares that outperformed the broader market as investors continued to pour money into companies maki
Pharma Mirror
FEBRUARY 4, 2022
Rockville, Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced its role as a Data Coordinating Center on a team whose work has accelerated pediatric COVID-19 research through the Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Scienmag
FEBRUARY 3, 2022
New Jersey Institute of Technology (NJIT) has reaffirmed its status among the nation’s most elite and productive research institutions by once again achieving an R1 status — the highest designation — by the Carnegie Classification. Credit: NJIT New Jersey Institute of Technology (NJIT) has reaffirmed its status among the nation’s most elite and productive research […].
Bio Pharma Dive
FEBRUARY 1, 2022
Despite the growing threat of drug-resistant bacteria, few new antibiotics are reaching the market because of hurdles that biotech executives and experts say stand in the way.
Pharma Times
FEBRUARY 4, 2022
Health and social care secretary will declare war on cancer with a decade-long plan to combat disease misery
Pharma Mirror
FEBRUARY 3, 2022
Everybody knows that life as a caretaker can get rough sometimes, but it also comes with its fair share of benefits. In this article, we aim to highlight some of the long-term benefits of wearing scrubs to work, day in and day out. Being youthful at heart and work Depending on the scrub policy you have at your place of work, charcoal grey scrubs can add a completely new layer to your professional attire.
Outsourcing Pharma
FEBRUARY 3, 2022
A leader from the artificial intelligence insights specialist talks discusses how the effective use of advanced analytics can lead to a number of benefits.
Bio Pharma Dive
FEBRUARY 4, 2022
In a regulatory filing, Biogen said the FTC and the SEC are looking for information about Aduhelm's approval and marketing, meaning the drug is now the focus of four government probes.
Pharma Times
FEBRUARY 1, 2022
Market authorisation for twice yearly schizophrenia treatment which offers patients much-needed medication continuity
Pharma Mirror
FEBRUARY 2, 2022
Global contract development and manufacturing organisation (CDMO), Recipharm, has today announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome. The acquisition forms part of Recipharm’s strategy to grow in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
FEBRUARY 3, 2022
India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum. While the regulatory framework for cannabinoid products remains fragmented and hard to navigate around the world, Germany has emerged as an early-mover.
Bio Pharma Dive
JANUARY 31, 2022
The biotech's drug is one of the few NASH treatments that has advanced to late-stage testing, as the disease has proven difficult for drugmakers to crack.
Pharma Times
FEBRUARY 1, 2022
Ayvakyt receives a positive opinion from the CHMP for the treatment of adults with advanced systemic mastocytosis
Pharma Mirror
JANUARY 30, 2022
This type of therapy is often offered by a licensed physical therapist who specializes specifically in young children and babies. It aims at improving a child’s mobility after an injury or illness. You can get these services at home, a daycare center, school, or an outpatient clinic. Typically, the treatment should be provided in a setting that the child feels comfortable.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Outsourcing Pharma
FEBRUARY 1, 2022
On World Cancer Day, the Union for International Cancer Control is launching a three-year campaign with the goal to improve cancer care around the globe.
Bio Pharma Dive
JANUARY 31, 2022
The drug, which will be sold as Vabysmo, is the first of several emerging competitive threats to Regeneron's top-selling Eylea, along with biosimilars and long-acting implants.
Pharma Times
FEBRUARY 2, 2022
Boost for patients with life-threatening conditions who require access to medicines not yet authorised for marketing
Pharma Mirror
JANUARY 30, 2022
Ben Beckley, Global Lead at EmerGENE explores the market challenges holding back Cell and Gene Therapy (C>) from taking its place as an established treatment area. He explains how we can navigate obstacles to ensure C> can achieve its full potential. As a treatment area, C> has shown robust growth in recent years. Some 3,366 treatments are currently in preclinical and clinical development[1].
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JANUARY 31, 2022
People with long-lasting symptoms of breathlessness after COVID-19 infection may have damage to their lungs that does not show up using routine diagnostic scans, according to a small UK study. The researchers from Oxford, Sheffield, Cardiff and Manchester universities used a new form of diagnostic that involves patients breathing in the inert gas xenon whilst undergoing an MRI scan, which allows them to gauge how well gases like oxygen are being transferred from the lungs to blood vessels.
Bio Pharma Dive
FEBRUARY 3, 2022
Executives for the pharma downplayed the impact of an accelerated approval for donanemab, pointing to Medicare's plans to restrict coverage of Alzheimer's drugs like it to only patients in clinical trials.
Pharma Times
JANUARY 31, 2022
Positive news for children aged six to 11 as Dupixent offers improved asthma treatment
Pharma Mirror
JANUARY 29, 2022
An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily. The IgY antibody technology, with an invention patent issued by China National Intellectual Property Association, was jointly unveiled by Sino-Swed Tongkang Biotech Ltd.
Expert insights. Personalized for you.
333 
Let's personalize your content